Understanding the Reimbursement Landscape for Prescription Digital Therapeutics

 Prescription Digital Therapeutics (PDTs) present a novel opportunity for companies to develop accessible, cost-effective therapeutics to treat unmet patient needs. With an increased focus on disruptive methods of delivering care accelerated by the COVID-19 pandemic, the overall digital therapeutics market is estimated to soar to more than $5 billion by 2027.
Coverage and reimbursement for PDTs is continuously evolving, and the successful commercialization of PDTs can involve a complex web of interrelated actors that work together to establish the necessary coding, coverage, and payment infrastructure that facilitates patient access across payers. Our panel will provide an overview of the current state of coverage and reimbursement in the commercial and public payer markets, recent developments and ongoing efforts to secure coverage and reimbursement for PDTs, and how your company can best position itself for the future.